The Savella Pregnancy Registry
Terminated · NCT01026077
Conditions: Fibromyalgia
At a glance
- Research payments reported, 2025
- $363
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 350
About the trial
- Sponsor
- Syneos Health (with AbbVie)
- Dates
- Started 2009-11; completion 2024-10-09
- Results posted
- Not yet
The Savella Pregnancy Registry is a US based registry designed to monitor pregnancies exposed to Savella (milnacipran HCI). This is an observational, exposure-registration and follow-up registry designed primarily to estimate the prevalence of major congenital anomalies, and secondarily to estimate the prevalence of recognized spontaneous abortions, stillbirths, induced abortions, minor congenital anomalies, and any serious adverse pregnancy outcomes among pregnancies exposed to Savella as well as adverse outcomes observed during the first year of life in off-springs born from these exposed pregnancies. Live offspring are followed from birth until age one. The Savella Pregnancy Registry i…
From ClinicalTrials.gov, last updated 2025-01-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $363 in research payments for this study in 2025 (1 payments).
Products named: Savella
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $363
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.